Lead Exposure Promotes NF2-wildtype Meningioma Cell Proliferation Through the Merlin-Hippo Signaling Pathway

Overview

Journal Environ Health Prev Med

Date 2025 Feb 2

PMID 39894505

Authors

Nenghua Zhang

Xiaohua Shen

Yunnong Yu

Long Xu

Zheng Wang

Jia Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Lead is a persistent inorganic environmental pollutant with global implication for human health. Among the diseases associated with lead exposure, the damage to the central nervous system has received considerable attention. It has been reported that long-term lead exposure increases the risk of meningioma; however, the underlying mechanism remains poorly understood. Clinical studies have indicated that loss-of-function and mutations in the neurofibromin-2 (NF2) gene play a crucial role in promoting meningioma formation.

Methods: The effect of Pb on meningioma were tested in-vitro and in-vivo. Two human meningioma cell lines were used in this study, including NF2-wildtype IOMM-Lee cell and NF2-null CH157-MN cell. Cell viability, cell cycle and cell size were examined after Pb exposure. The expression of Merlin, mammalian sterile 20-like kinases 1 and 2 (MST1/2) and Yes-associated protein (YAP) from these two meningioma cells were analyzed by Western blot. A xenograft mouse model was constructed by subcutaneous injection of IOMM-Lee meningioma cells.

Results: This study demonstrated that treatment with lead induce dose-dependent proliferation in IOMM-Lee cell (with an EC value of 19.6 µM). Moreover, IOMM-Lee cell exhibited augmented cell size in conjunction with elevated levels of phosphorylated histone H3, indicative of altered cell cycle progression resulting from lead exposure. However, no significant change was observed in the CH157-MN cell. Additionally, the Merlin-Hippo signaling pathway was inactivated with decreased Merlin and phosphorylation levels of MST1/2 and YAP, leading to increased YAP nuclear translocation in IOMM-Lee cells. However, there was no change in the Merlin-Hippo signaling pathway in CH157-MN cells after lead treatment. The administration of Pb resulted in an acceleration of the subcutaneous IOMM-Lee meningioma xenograft growth in mice.

Conclusions: Overall, the current study elucidates the potential mechanism by which lead exposure promotes the proliferation of meningioma with NF2 expression for the first time.

References

Goldbrunner R, Stavrinou P, Jenkinson M, Sahm F, Mawrin C, Weber D . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23(11):1821-1834. PMC: 8563316. DOI: 10.1093/neuonc/noab150. View

Posser T, de Aguiar C, Garcez R, Rossi F, Oliveira C, Trentin A . Exposure of C6 glioma cells to Pb(II) increases the phosphorylation of p38(MAPK) and JNK1/2 but not of ERK1/2. Arch Toxicol. 2007; 81(6):407-14. DOI: 10.1007/s00204-007-0177-6. View

Kwon J, Oh J, Seok S, An H, Lee Y, Lee N . Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency. Mol Cancer. 2023; 22(1):156. PMC: 10510129. DOI: 10.1186/s12943-023-01857-0. View

Calabrese E, Baldwin L . Lead-induced cell proliferation and organ-specific tumorigenicity. Drug Metab Rev. 1992; 24(3):409-16. DOI: 10.3109/03602539208996299. View

Grandjean P . Even low-dose lead exposure is hazardous. Lancet. 2010; 376(9744):855-6. DOI: 10.1016/S0140-6736(10)60745-3. View

Gu C, Chen S, Xu X, Zheng L, Li Y, Wu K . Lead and cadmium synergistically enhance the expression of divalent metal transporter 1 protein in central nervous system of developing rats. Neurochem Res. 2008; 34(6):1150-6. DOI: 10.1007/s11064-008-9891-6. View

Leroyer A, Gomajee H, Leroy R, Mazzuca M, Leleu B, Nisse C . Cancer mortality and chemical exposure in a retrospective zinc and lead smelter cohort: A 48-year follow-up. Int J Hyg Environ Health. 2022; 242:113955. DOI: 10.1016/j.ijheh.2022.113955. View

Marshall A, Betts S, Kan E, McConnell R, Lanphear B, Sowell E . Association of lead-exposure risk and family income with childhood brain outcomes. Nat Med. 2020; 26(1):91-97. PMC: 6980739. DOI: 10.1038/s41591-019-0713-y. View

Zanconato F, Cordenonsi M, Piccolo S . YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016; 29(6):783-803. PMC: 6186419. DOI: 10.1016/j.ccell.2016.05.005. View

10.

Dorea J . Environmental exposure to low-level lead (Pb) co-occurring with other neurotoxicants in early life and neurodevelopment of children. Environ Res. 2019; 177:108641. DOI: 10.1016/j.envres.2019.108641. View

11.

Liu Y, Ren H, Zhou Y, Shang L, Zhang Y, Yang F . The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming. J Exp Clin Cancer Res. 2019; 38(1):228. PMC: 6540399. DOI: 10.1186/s13046-019-1219-7. View

12.

Honda D, Okumura M, Chihara T . Crosstalk between the mTOR and Hippo pathways. Dev Growth Differ. 2023; 65(6):337-347. DOI: 10.1111/dgd.12867. View

13.

Cordova C, Kurz S . Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Curr Oncol Rep. 2020; 22(8):84. DOI: 10.1007/s11912-020-00937-4. View

14.

Gan W, Dai X, Dai X, Xie J, Yin S, Zhu J . LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020; 22(2):246-256. PMC: 7076906. DOI: 10.1038/s41556-020-0463-6. View

15.

Lee S, Karas P, Hadley C, V J, Khan A, Jalali A . The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers (Basel). 2019; 11(11). PMC: 6893739. DOI: 10.3390/cancers11111633. View

16.

Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy R . Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int J Mol Sci. 2021; 22(2). PMC: 7828193. DOI: 10.3390/ijms22020690. View

17.

Sahebjam S, Gilbert M . Modeling YAP fusions: a paradigm for investigating rare cancers?. Genes Dev. 2022; 36(15-16):874-875. PMC: 9575698. DOI: 10.1101/gad.350069.122. View

18.

Lu H, Guizzetti M, Costa L . Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase Calpha. J Neurochem. 2001; 78(3):590-9. DOI: 10.1046/j.1471-4159.2001.00434.x. View

19.

Kotecha R, Pascoe E, Rushing E, Rorke-Adams L, Zwerdling T, Gao X . Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011; 12(13):1229-39. DOI: 10.1016/S1470-2045(11)70275-3. View

20.

Cunningham R, Hansen C . The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022; 136(3):197-222. PMC: 8819670. DOI: 10.1042/CS20201474. View